Core Insights - Cuba's biopharmaceutical industry has made significant progress despite the long-standing U.S. blockade, focusing on public health needs and integrating research, production, and commercial aspects [1][2] - The blockade has led to severe shortages of raw materials and equipment, causing persistent drug shortages, which the Cuban government is attempting to mitigate through international cooperation and supply chain diversification [1][3] Investment and Development - The Cuban government has heavily invested in human capital and scientific development, establishing a biopharmaceutical system that has gained international recognition for its contributions to public health [1][2] - The establishment of the Biopharmaceutical Group in 2012 has consolidated over 40 biotechnology and pharmaceutical companies, improving quality standards and resource efficiency [2] Challenges and Shortages - The U.S. blockade has resulted in a 95% reliance on imported raw materials for drug production, with equipment failures contributing to 5% of production halts [3] - As of 2025, 69% of the essential drug list is affected by the blockade, with 364 out of 651 drugs in short supply, representing 56% of the total [3] International Cooperation - To counteract the pressures of the blockade, Cuba is deepening international cooperation, with Latin America being the primary export market and Africa emerging as a new growth area [4] - Collaborative projects, such as those announced at the St. Petersburg International Economic Forum, aim to develop drugs for aging and cancer, enhancing Cuba's biopharmaceutical capabilities [4][5] Future Prospects - Cuba's recent accession as a BRICS partner country is expected to provide new avenues for financing, technology support, and market diversification, potentially alleviating the constraints imposed by the U.S. blockade [5]

Core Viewpoint - Global solidarity is essential to end the AIDS epidemic, as emphasized by Winnie Byanyima, Executive Director of the UNAIDS, during an interview [3][5]. Group 1: Progress in AIDS Control - Significant progress has been made in combating AIDS over the past decades, with a notable decline in new HIV infections and AIDS-related deaths since 2010 [3]. - In 2023, nearly 31 million people are receiving antiretroviral therapy, which is one of the most effective means to control the AIDS epidemic [3][5]. Group 2: Importance of International Cooperation - The success in fighting AIDS is attributed to the collective efforts of countries, particularly in supporting those with heavier burdens [3][5]. - Continuous international cooperation is necessary to achieve the goal of ending the AIDS epidemic by 2030, as some countries have reduced foreign aid and budgets impacting AIDS prevention efforts [3][5]. Group 3: Role of Education and Gender Equality - Addressing social challenges, including education and gender equality, is crucial in preventing new infections, especially in sub-Saharan Africa where women and girls are significantly affected [5]. - Keeping girls in school is highlighted as one of the most effective ways to prevent them from contracting HIV [5]. Group 4: Technological Innovations - Recent technological innovations, such as the new antiretroviral drug lenacapavir, are seen as potential breakthroughs in AIDS treatment [5]. - There is a call for governments, businesses, and international organizations to collaborate in making new technologies and medications accessible to more populations [5]. Group 5: Holistic Approach to AIDS Prevention - Combating AIDS requires more than just reliance on medication; lifestyle changes and achieving social equality are also important defenses [6].